2023-04-17 17:27:00 ET
- Innoviva ( NASDAQ: INVA ) said the U.S. Food and Drug Administration's advisory committee unanimously voted in support of approval of sulbactam-durlobactam to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex.
- The FDA advisory committee voted 12-0 in favor of the approval.
- The FDA is scheduled to decide on the approval by May 29, and typically follows the recommendations of its independent panel of experts.
- ( INVA ) is up ~6% .
- Press Release
For further details see:
Innoviva rises 6% on FDA panel backing for bacterial pneumonia drug